Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
OBJECTIVE
Clinical studies show that Asians (ASN) are more susceptible to toxicities associated with platinum-containing regimens. We hypothesized that studying ASN as an 'enriched phenotype' population could enable the discovery of novel genetic determinants of platinum susceptibility.


METHODS
Using well-genotyped lymphoblastoid cell lines from the HapMap, we determined cisplatin and carboplatin cytotoxicity phenotypes (IC50s) for ASN, Caucasians (CEU), and Africans (YRI). IC50s were used in genome-wide association studies.


RESULTS
ASN were most sensitive to platinums, corroborating clinical findings. ASN genome-wide association studies produced 479 single-nucleotide polymorphisms (SNPs) associating with cisplatin susceptibility and 199 with carboplatin susceptibility (P<10). Considering only the most significant variants (P<9.99x10), backwards elimination was then used to identify reduced-model SNPs, which robustly described the drug phenotypes within ASN. These SNPs comprised highly descriptive genetic signatures of susceptibility, with 12 SNPs explaining more than 95% of the susceptibility phenotype variation for cisplatin, and eight SNPs approximately 75% for carboplatin. To determine the possible function of these variants in ASN, the SNPs were tested for association with differential expression of target genes. SNPs were highly associated with the expression of multiple target genes, and notably, the histone H3 family was implicated for both drugs, suggesting a platinum-class mechanism. Histone H3 has repeatedly been described as regulating the formation of platinum-DNA adducts, but this is the first evidence that specific genetic variants might mediate these interactions in a pharmacogenetic manner. Finally, to determine whether any ASN-identified SNPs might also be important in other human populations, we interrogated all 479/199 SNPs for association with platinum susceptibility in an independent combined CEU/YRI population. Three unique SNPs for cisplatin and 10 for carboplatin replicated in CEU/YRI.


CONCLUSIONS
Enriched 'platinum susceptible' populations can be used to discover novel genetic determinants governing interindividual platinum chemotherapy susceptibility.
O'Donnell
Peter H
PH
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
Gamazon
Eric
E
Zhang
Wei
W
Stark
Amy L
AL
Kistner-Griffin
Emily O
EO
Stephanie Huang
R
R
Eileen Dolan
M
M
D044466:Asian People; D044383:Black People; D016190:Carboplatin / Q000494:pharmacology; D002461:Cell Line, Transformed; D002945:Cisplatin / Q000494:pharmacology; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005828:Genetics, Population; D055106:Genome-Wide Association Study; D006801:Humans; D020128:Inhibitory Concentration 50; D008214:Lymphocytes / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D010984:Platinum / Q000494:pharmacology*; D044465:White People
D010984:Platinum; D016190:Carboplatin; D002945:Cisplatin
Clin Cancer Res. 2005 Feb 15;11(4):1534-8
15746057
Biochim Biophys Acta. 2002 Dec 12;1579(2-3):142-52
12427549
J Biol Chem. 2004 May 14;279(20):20622-5
15010460
Eur J Cancer Clin Oncol. 1988 Feb;24(2):255-62
3281842
Clin Pharmacol Ther. 2008 Sep;84(3):287-94
18714314
Nat Chem Biol. 2008 Feb;4(2):110-2
18157123
Cancer Res. 2004 Jun 15;64(12):4353-6
15205351
Lung Cancer. 2007 Aug;57(2):143-51
17420066
Nat Genet. 2007 Oct;39(10):1217-24
17873874
Am J Hum Genet. 2007 Sep;81(3):559-75
17701901
Cell. 2010 Jan 22;140(2):183-95
20141833
Jpn J Clin Oncol. 2002 Feb;32(2):48-53
11948228
PLoS Genet. 2010 Apr 01;6(4):e1000888
20369019
Am J Hum Genet. 1999 Dec;65(6):1718-24
10577926
J Clin Oncol. 1996 Mar;14(3):1043-4
8622011
Oncol Rep. 2003 Jul-Aug;10(4):951-5
12792751
PLoS Genet. 2009 Aug;5(8):e1000592
19662163
Clin Pharmacol Ther. 2008 Sep;84(3):417-23
18615002
Immunobiology. 2003;207(5):351-9
14575150
Hum Hered. 2007;63(2):85-92
17283437
Cancer Res. 2007 Jun 1;67(11):5425-33
17545624
Nat Genet. 2007 Feb;39(2):226-31
17206142
Clin Cancer Res. 2006 Jan 1;12(1):131-8
16397034
Pharmacogenomics. 2005 Apr;6(3):303-10
16013961
Cancer Treat Rev. 2007 Oct;33(6):565-77
17707593
Nature. 2005 Oct 27;437(7063):1299-320
16255080
Ann Oncol. 2003 Mar;14(3):449-54
12598352
Anticancer Drugs. 2003 Nov;14(10):801-7
14597874
Hum Genomics. 2009 Jan;3(2):128-42
19164090
J Clin Oncol. 2007 Oct 10;25(29):4513-5
17925544
Nat Rev Genet. 2005 Feb;6(2):95-108
15716906
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63
17537913
Nat Genet. 2007 Oct;39(10):1202-7
17873877
Pharmacogenet Genomics. 2008 Mar;18(3):253-62
18300947
PLoS One. 2009;4(3):e4684
19259268
Int J Oncol. 2004 Jun;24(6):1407-12
15138581
Mol Cancer Ther. 2007 Jan;6(1):31-6
17237264
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
12883005
Am J Hum Genet. 2007 Sep;81(3):427-37
17701890
Cancer Treat Rev. 2007 Feb;33(1):9-23
17084534